Core Insights - 60 Degrees Pharmaceuticals has entered a sponsored research agreement with Tulane University to study the effectiveness of tafenoquine against Borrelia and Bartonella, which are significant pathogens in Lyme disease [1][3] - The study aims to address the unmet need for effective treatments for tick-borne diseases, particularly in patients with co-infections [3] Company Overview - 60 Degrees Pharmaceuticals focuses on developing new medicines for infectious diseases and achieved FDA approval for its lead product, ARAKODA (tafenoquine), for malaria prevention in 2018 [16] - The company collaborates with research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private investors [16] Product Information - Tafenoquine is an 8-aminoquinoline antimalarial drug approved for malaria prophylaxis, with a long terminal half-life of approximately 16 days, allowing for less frequent dosing [5] - ARAKODA is not approved for the treatment or prevention of babesiosis, Borrelia, or Bartonella [4][5] Research Significance - The study at Tulane University will further investigate tafenoquine's potential in treating co-infections in patients suffering from babesiosis [3] - Understanding the interactions between these pathogens is crucial for developing effective treatments for Lyme disease and related conditions [2][3]